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Genetic variability is a hallmark of RNA virus populations. However, transmission to a new host often results in a marked de-
crease in population diversity. This genetic bottlenecking is observed during hepatitis C virus (HCV) transmission and can arise
via a selective sweep or through the founder effect. To model HCV transmission, we utilized chimeric SCID/Alb-uPAmice with
transplanted human hepatocytes and infected themwith a human serumHCV inoculum. E1E2 glycoprotein gene sequences in
the donor inoculum and recipient mice were determined following single-genome amplification (SGA). In independent experi-
ments, using mice with liver cells grafted from different sources, an E1E2 variant undetectable in the source inoculumwas se-
lected for during transmission. Bayesian coalescent analyses indicated that this variant arose in the inoculum pretransmission.
Transmitted variants that established initial infection harbored key substitutions in E1E2 outside HVR1. Notably, all posttrans-
mission E1E2s had lost a potential N-linked glycosylation site (PNGS) in E2. In lentiviral pseudoparticle assays, the major post-
transmission E1E2 variant conferred an increased capacity for entry compared to the major variant present in the inoculum.
Together, these data demonstrate that increased envelope glycoprotein fitness can drive selective outgrowth of minor variants
posttransmission and that loss of a PNGS is integral to this improved phenotype. Mathematical modeling of the dynamics of
competing HCV variants indicated that relatively modest differences in glycoprotein fitness can result in marked shifts in virus
population composition. Overall, these data provide important insights into the dynamics and selection of HCV populations
during transmission.
Hepatitis C virus (HCV) is a positive-sense RNA envelopedvirus belonging to the genus Hepacivirus within the family
Flaviviridae. Globally, an estimated 170 million people are in-
fected with HCV. Only about 15 to 20% of the population resolve
acute HCV infection; the vast majority go on to develop a chronic
infection, which is implicated in liver cirrhosis and hepatocellular
carcinoma (65, 66). HCV continues to represent a significant
global health burden, and vaccines to prevent new infections are
much needed.
HCV circulates within an infected host as a swarm of geneti-
cally distinct but closely related variants (7). This genetic variabil-
ity is unevenly distributed throughout the viral genome. Themost
variable regions are the E1E2 genes encoding the envelope glyco-
proteins (30). Both E1 and E2 are heavily glycosylated, and these
glycans have been shown to be integral in protein folding, cell
entry, and antibody shielding (23, 24). E1E2 evolution is driven by
a combination of positive and purifying selection and neutral se-
quence drift (5, 59). Functional requirements for receptor bind-
ing, membrane fusion, and entry (17) exert a strong purifying
effect, but it is set against the need for the virus to escape host
antibody responses (27), which often target epitopes that overlap
or are proximal to these functionally important regions (26, 32,
50, 52, 55, 63). Therefore, E1E2 evolution is driven by a subtle
interplay between functional constraint and immune escape.
HCV is primarily transmitted via the transcutaneous route.
Prior to the discovery of HCV and establishment of robust blood-
screening techniques, a major route of infection was via transfu-
sion of contaminated blood or blood products. Currently, the
major risk factor in countries with well-developed screening pro-
cedures is intravenous drug use (1). Additionally, health care
worker needle-stick injury (22, 46), transmission between sexual
partners (6), horizontal and vertical intrafamilial transmission
(9), and mother-to-child transmission (68) have all been re-
ported. Although nosocomial and iatrogenicHCV transmission is
rare inWestern nations (64), these routes of transmission are still
a major source of new infections in developing countries; for ex-
ample, in Egypt, there are an estimated 500,000 new infections
annually (44).
Development of an effective vaccine will need to elicit immu-
nity that targets those variants that are successfully transmitted.
Heterosexual transmission of HIV-1 often results in a significant
virus population bottleneck due to the founder effect, where a
single virus establishes the initial infection (14, 56). Characteriza-
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tion of the envelope glycoproteins from these founder viruses has
shown that they have an increased sensitivity to antibody-medi-
ated neutralization (14). In contrast, in HIV-1 transmission in
men who have sex with men and in intravenous drug users
(IDUs), there is wide variation in the number of viral strains that
initiate the new infection (3, 33).
Studying HCV transmission is challenging because most cases
of acute infection are asymptomatic and therefore go unnoticed.
Most studies of acute infection have utilized samples obtained
after seroconversion, when the virus has already been exposed,
and responded, to the early immune response. A number of stud-
ies have been performed using samples obtained during acute in-
fection of humans and chimpanzees, and the restricted diversity
observed posttransmission indicates that productive infection is
initiated by a single or a limited number of viral variants (8, 34, 36,
54, 60, 67). However, there are few studies that have tracked the
entire transmission process from donor to recipient, and those
that have, have focused on analysis of the first hypervariable re-
gion (HVR1) of E2 in the chimpanzee model (54, 60). Other re-
gions of the envelope glycoproteins contain important functional
and neutralizing determinants (16, 26, 27, 32, 43, 48–50, 52, 63),
and the natural histories of HCV infection in chimpanzees and
humans differ. Very limited studies on liver transplant cohorts
have shown that reinfection of grafts is characterized by E1E2
variants that permit efficient entry and exhibit neutralization-re-
sistant phenotypes (20). However, the presence of naturally oc-
curring neutralizing antibodies in transplant patients and post-
transplant therapy undoubtedly influences reinfection.
Envelope glycoprotein determinants that define the ability of
HCV to establish infection in a new host have not been identified.
Such insight will be critical for the rational design of entry-tar-
geted strategies that prevent HCV infection. To address this sig-
nificant shortfall, we have utilized single-genome amplification
(SGA) of E1E2 genes to study transmission of serum-derived
HCV to SCID/Alb-uPA chimeric mice with grafted human liver
cells (29, 41). This small-animalmodel is ideal for these studies, as
infection is established in grafted human liver cells, and the lack of
an adaptive immune response provides a good surrogate for the
acute phase of infection. Comparative analyses of donor and re-
cipient sequences were performed, in conjunction with a range of
phylogenetic tests. Importantly, recovery of full-length E1E2s also
enabled us to investigate the phenotypic consequences of E1E2
selection upon transmission. Together, our data reveal important
E1E2 determinants facilitating successful HCV transmission and
establishment of initial infection in a new host.
MATERIALS AND METHODS
Source of samples. HCV RNA samples were obtained as described in a
previously published study (32). Briefly, 11 human liver-chimeric SCID/
Alb-uPA mice, transplanted with human hepatocytes from different do-
nors, were inoculated intrajugularly with 100 l genotype 1a HCV-in-
fected serum KP (2.3 106 IU/ml). The infections were monitored over
time (Table 1) by tail bleed sampling. HCV RNA in mouse serum was
quantified by a real-time 24 TaqMan PCR assay (32). RNA was recovered
from serum aliquots using a commercially available RNA extraction kit
(Qiagen) and resuspended in 20 l of H2O. Donor serum (KP) was ob-
tained from anHCV patient in the chronic phase of infection, with time
since initial infection estimated at 5 years.
All mice were housed and treated according to Canadian Council on
Animal Care guidelines. Experimental approval came from theUniversity
of Alberta Animal Welfare Committee, and human sera and hepatocytes
were obtained following informed written consent of all donors with eth-
ics approval from the University of Alberta, Faculty of Medicine Research
Ethics Board.
SGA of HCV E1E2. To accurately assess the dynamics of HCV trans-
mission, an SGA approach was employed, followed by direct sequencing
(12). Full-length E1E2 sequences (amino acids 170 to 746, corresponding
to the polyprotein sequence of the reference strain H77 [accession no.
NC_004102]) from sequential samples (2 time points) derived from 4
HCV-infected chimeric mice (666, 714, 594, and 931) and donor inocu-
lum (KP) were amplified, using previously described primers (31). Nine
microliters of HCV RNA was used in a 20-l reverse transcription reac-
tion with 10 pmol primer OAS 1a using a commercially available Ther-
moscript cDNA synthesis kit (Invitrogen) according to the manufactur-
er’s protocol. The resulting viral cDNAswere serially diluted, and aliquots
of 2-fold dilutions (1 l) were used as templates in the first round of a
nested full-length E1E2 PCR. Amplification reactions were set up in 20-l
volumes containing 4 pmol of primer OAS 1a and primer EOS (31), 200
mM deoxynucleoside triphosphates (dNTPs), 0.5 U of Platinum Taq
High Fidelity polymerase (Invitrogen), 1High Fidelity polymerase buf-
fer, and 2mMMgSO4. The PCR cycling parameters were as follows: initial
denaturation at 94°C for 2min, followed by 35 cycles of 94°C for 15 s, 50°C
for 30 s, and 68°C for 3min, with a final extension step at 68°C for 10min.
Twomicroliters of first-round product was subsequently used as the tem-
plate in second-round reactions with primers 1ASGT1a and 170gt1, using
amplification and cycling conditions identical to the first round but in-
creasing the cycle number to 45. Amplification of a 2-fold dilution series
of cDNA titration PCRs revealed the dilution at which the concentration
of viral cDNA was 1 molecule per l. Subsequently, multiple E1E2
amplicons for each sample were generated at this endpoint dilution (to
give a frequency of 3/10 PCR-positive reactions). The amplification
products were directly sequenced using BigDye v1.1 (Applied Biosys-
tems). Chromatographs were manually inspected, and amplicons exhib-
iting dual peaks at a single nucleotide position, resulting from amplifica-
tion from 1 starting template molecule, were excluded from further
analysis.
Sequence analysis and phylogenetic reconstruction. Nucleotide se-
quences were aligned according to overlying amino acid translations. Align-
TABLE 1 Summary of sample detailsa
Patient/
mouse
ID
Population
sampling
Serum
HCV
(IU/ml)
Hepatocyte
donora
Time
postinoculation
(days)
No. of SGA
ampliconsb
KP KP 1 106 36
A594 594_1 8.09 105 II 32 13 bulk
594_2 1.01 106 II 59 17
N666c 666_1 2.69 106 I 14 22
666_2 2.49 106 I 28 20
N714c 714_1 1.16 106 I 14 21
714_2 1.54 106 I 28 19
A931 931_1 8.61 107 III 21 11
931_2 2.94 107 III 42 13
A931 8.04 107 III 28 NA, bulk
A594 A594 8.09 105 II 32 NA, bulk
A583 A583 8.40 105 II 32 NA, bulk
A596 A596 1.73 105 II 32 NA, bulk
A585 A585 2.99 105 II 32 NA, bulk
A587 A587 9.79 106 II 32 NA, bulk
A902 A902 4.46 107 III 28 NA, bulk
A909 A909 1.96 107 III 28 NA, bulk
A965 A965 7.73 106 III 28 NA, bulk
a I, 36-year-old female; II, 45-year-old female, 92% viability polycystic tissue; III, 4-
year-old male, 92% viability normal tissue.
b Bulk indicates samples for which majority consensus sequences were generated on
undiluted cDNA samples. NA, not applicable.
c Mouse N666 and mouse N714 were control mice in the HCV monoclonal antibody
protection study previously reported (32).
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ments were performed using Mega 4.0 (62), with manual adjustment to en-
sure maintenance of the open reading frame. Substitutions occurring across
viral populations were visualized using the Highlighter Tool (http://hcv.lanl
.gov/content/sequence/HIGHLIGHT/highlighter.html), where the KP con-
sensus sequence was used as a master sequence. Consensus sequences were
generated using the Consensus Maker tool (http://hcv.lanl.gov/content
/sequence/CONSENSUS/consensus.html). Phylogenetic relationships be-
tween generated E1E2 sequences were calculated utilizing the maximum-
likelihood (ML) criterion implemented by PAUP version 4.0b10 (61) using
thebest-fit substitutionmodel for thedata calculated inModeltest version3.7
(53). ML trees were rooted on the consensus sequence from the donor inoc-
ulum (KP_con).
Assessment of the number of transmitting variants and evolution-
ary rates. To define the number of variants that established initial infec-
tion followingmouse inoculation and to estimate substitution rates, time-
scaled phylogenies of each data set were generated using a BayesianMonte
Carlo Markov Chain (MCMC) method implemented in BEAST (version
1.6.0; available from http://beast.bio.ed.ac.uk/) (18, 19, 58). Evolutionary
rate estimates and phylogenies were obtained using the SRD06model and
two relaxed clock models: uncorrelated lognormal and uncorrelated ex-
ponential. The MCMC search was set to at least 10,000,000 iterations, so
that the effective sampling size for the parameters under study reached
more than 200. Trees were sampled every 1,000th generation with a 10%
burn-in and then summarized using Tree Annotator v.1.6.0 (also avail-
able from http://beast.bio.ed.ac.uk/). The most appropriate model was
identified by calculating the Bayes factor (BF) using the program Tracer
v1.5 (http://beast.bio.ed.ac.uk/). Phylogenies were visualized using
FigTree v1.3.1. Branches that had a time tomost recent common ancestor
(tMRCA) estimated to have occurred after the known time of inoculation
were collapsed to enable identification of the number of effective trans-
mitting variants that establish initial infection.
Patient HLA typing and epitope prediction.Donor KP’s HLA class I
and II genotype was determined by the histocompatibility laboratory at
the University of Alberta Hospital (Edmonton, AL, Canada) using a low-
resolution PCR method with sequence-specific primer mixes. E1E2
epitopes previously reported to be presented by the donor’s HLA class I
alleles were identified with the help of the Immune Epitope Database
(http://www.immuneepitope.org/). Peptides that were likely to be pre-
sented by the donor HLA class I alleles were predicted using the
SYFPEITHI (http://www.syfpeithi.de/home.htm) and BIMAS (http:
//www-bimas.cit.nih.gov/molbio/hla_bind/) websites.
HCV pseudovirus infection. HCV E1E2 sequences, bearing one of 4
possible key residue combinations (SNHV, SDHV, TDYD, and TDYV)
were ligated into a pcDNA3.1 V5D-TOPOmammalian expression vector
(Invitrogen). The rare transitory variant (SDYV) and the minority post-
transmission variant TDYA were not tested (V/A have very similar
physiochemical properties). Huh-7.5 cells were propagated in Dulbecco’s
Modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS)-1% nonessential amino acids. Primary human hepatocytes
were isolated according to a previously published protocol (45) and were
maintained in Williams E medium supplemented with 10% FBS-5 mM
HEPES-insulin-dexamethasone. The cells were plated at 4 104 cells/cm2
and infected the following day. Pseudoviruses were generated by trans-
fecting 293T cells with plasmids encoding human immunodeficiency vi-
rus gag/pol, luciferase, and either HCV E1E2 glycoproteins, vesicular sto-
matitis virus glycoprotein (VSV-G), or no-envelope (E1E2) control as
previously reported (25). Supernatants were harvested 48 h posttransfec-
tion, clarified, and filtered through a 0.45-mmembrane. Virus-contain-
ing medium was incubated with target cells for 8 h in the presence or
absence of anti-CD81 monoclonal antibody 2s131 (40) (5 g/ml) over-
night, unbound virus was removed, and the medium was replaced with
DMEM containing 3% FBS. At 72 h postinfection, the medium was re-
moved and the cells were lysed with cell lysis buffer (Promega, Madison,
WI). Luciferase activity was determined by the addition of luciferase sub-
strate and measured for 10 s in a luminometer (Lumat LB 9507).
Mathematical modeling. An ordinary differential equation model
was employed to analyze the dynamics of two competing HCV variants.
The model is an extension of the basic model used to represent viral
dynamics (51), incorporating twoHCV variants and neglecting the effects
of treatment in order to reflect the conditions of our study. Certain as-
sumptions are required to formulate the model: target cells (T) are pro-
duced at rate , die at rate d, and are infected by variant 1 (V1) at rate k and
by variant 2 (V2) at rate k, where  is1 (reflecting a fitness advantage
for variant 2); infected cells (I1 and I2) die at rate 	. We assume equal
production and clearance rates for both variants: p and c, respectively. The
equations are thus dT/dt
 dT kV1TkV2T, dI1/dt
 kV1T	I1,
dI2/dt
 kV2T 	I2, dV1/d2
 pI1 cV1, and dV2/d2
 pI2 cV2.
For simplicity, only two variants are considered (though we can as-
sume V1 accounts for all variants except TDYV/A, which is given by V2),
but themodel could be easily extended to consider any number. Tomatch
our data, we set I1 (0) equal to I2 (0) equal to 0 cells ml
1 to reflect all host
cells initially being healthy, and we assume that variant 1 formed 99% of
our initial inoculum,with variant 2making up the remaining 1%; thus,V1
(0) is equal to 2.277 106 and V2 (0) is equal to 2.3 10
4 virions ml1.
From Dahari et al. (13), we take the initial concentration of target liver
cells to be 1.87 107 cellsml1 and scale this by 0.7 to reflect our chimeric
livers consisting of 70% human cells, making T (0) equal to 1.309 107
cells ml1. Neumann et al. (47) estimated viral reproduction and infec-
tion rates to be as follows: P
 100 virions cell1 day1 and k
 3 107
ml virion1 day1. In addition, the viral clearance rate and infected-cell
death rate are assumed to be as follows: c
 5 days1 and 	 
 0.5 day1
(corresponding to half-lives of 2.7 h and 12 h, respectively). However,
given that our mouse model is immunodeficient, we investigated a range
of c and 	 values decreasing from those stated above. Half-life estimates of
target cells ranged from 50 to 500 days (13). We investigated both ex-
tremes of this interval, considering the following: 0.013  d  0.0014
day1. Finally, assuming that, in the absence of a viral load the target cell
concentration is at quasi-steady state (dT/dt
 0), we take  to be equal to
dT (0). The equations were solved numerically inMatlab 7.12.0 (R2011a).
RESULTS
Experimental transmissions.Defining the genotypic and pheno-
typic envelope glycoprotein determinants underlying successful
HCV transmission is challenging, as natural acute infection is of-
ten asymptomatic. To overcome this limitation, we used the well-
defined and robust human liver-chimeric SCID/Alb-uPA mouse
model to studyHCVenvelope glycoprotein evolution at transmis-
sion. Eleven chimericmice, transplanted with human hepatocytes
from different donors, were inoculated via the intrajugular route
with 100 l genotype 1a HCV-infected serum KP (2.3 106 IU/
ml) to simulate natural exposure to virus. In total, we obtained 36
SGA E1E2 sequences from the KP inoculum and 136 temporally
sampled SGA E1E2 sequences derived from viruses circulating in
four recipient chimericmice (24 to 44 sequences for each chimeric
mouse; 11 to 22 sequences for each time point). For the purposes
of comparison, bulk E1E2 amplifications were also performed for
the seven additional experimentally infected chimericmice (Table
1). As an internal experimental control, bulk E1E2 ampliconswere
also generated and sequenced for chimeric mice 594 and 931. Im-
portantly, SGA of full-length E1E2 enabled us to investigate the
phenotypic consequences of E1E2 upon transmission.
Molecular determinants underlying experimental HCV
transmission. To define E1E2 sequence evolution during these
experimental HCV transmission events, nucleotide sequences de-
rived from the donor inoculum and recipient mice were com-
bined and subjected to phylogenetic analyses (Fig. 1). There were
two major clades evident, one containing the majority of the do-
nor inoculum sequences and a second containing the mouse-de-
Brown et al.
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rived sequences and two donor sequences (KP7 and KP22). The
sequences derived from the recipient mice were interspersed with
one another, and there was no evidence of clustering according to
individual recipient mice.
To determine whether HVR1 sequences altered following
transmission, we determined the relative frequency of eachHVR1
deduced amino acid sequence in the inoculum and recipientmice.
A total of sevenHVR1 amino acid variants were identified (HVR1
A to G) (Fig. 2A), and the frequency distribution of these seven
variants revealed that the major HVR1 sequence in donor plasma
was also the majority variant in all recipient chimeric mice (Fig.
2B). The majority sequence (HVR1 A) occurred in 83% of all
analyzed sequences. This HVR1 variant represented over 86% of
donor sequences and constituted 100% of HVR1 sequence popu-
lations circulating in mice 594 and 931. None of the minor HVR1
variants present in the KP inoculum (HVR1 C to F) were trans-
mitted to recipient chimericmice. Chimericmice 714 and 666 also
yielded another sequence variant (HVR1 B) that was not detected
in the donor. This variant constituted over 42% of the HVR1
sequence population in chimeric mouse 714. This mouse also
contained an additional minor variant (HVR1 G). All of the new
HVR1 variants arose through a single amino acid substitution.
These data show that there are no major differences in the HVR1
regions of viruses obtained pre- and posttransmission and indi-
cate that determinants associated with successful transmission re-
side outside HVR1.
To investigate this further, full-length E1E2 sequences were
analyzed using a combination of phylogenetic analyses and High-
lighter plots (Fig. 3A to D). Although the overall intrahost se-
quence diversity was low, multiple distinct variants were identi-
fied in the donor and in each recipient. Highlighter plots and
phylogenetic trees revealed mutational patterns associated with
pre- and posttransmission populations. These data revealed a
consistent pattern of nonsynonymous (amino acid- changing)
substitutions associated with transmission, irrespective of the chi-
meric mouse recipient, which were distributed throughout the
E1E2 genes. Analysis of the deduced amino acid sequence align-
ments identified four E1E2 amino acid substitutions at positions
198, 448, 474, and 570 that were associated with productive infec-
tion in the recipient mice (Fig. 4A). The residues at positions 198,
448, 474, and 570 appeared in one of 5 possible combinations:
SNHV, SDHV, TDYD, SDYV, and TDYV/A. The frequencies of
these motifs in the SGA sequence data set obtained for the inocu-
lum and the recipient chimeric mice are summarized in Fig. 4B.
Themajor E1E2 variant in the inoculumpopulation possessed the
SNHV motif. This combination was evident in approximately
90% of all the donor E1E2 amplicons. However, this sequence
motif was undetectable in all recipient chimeric mice. Without
exception, all of the mouse-derived sequences contained the
FIG 1 Combined phylogenetic reconstruction of donor and recipient viral
E1E2 populations. Shown is a maximum-likelihood tree (HKY  ) derived
using SGA and bulk E1E2 sequences present in the KP donor inoculum and in
chimeric mice posttransmission. Red circles, KP inoculum; green squares,
mouse 594 time point 1; green triangles, mouse 594 time point 2; black
squares, mouse 666 time point 1; black triangles, mouse 666 time point 2; blue
squares, mouse 714 time point 1; blue triangles, mouse 714 time point 2;
pink squares, mouse 931 time point 1; pink triangles, mouse 931 time point 2;
turquoise circles, bulk amplified sequences. The scale bar is proportional to the
genetic distance and represents 0.0005 nucleotide substitution per site.
HCV Transmission
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N448D substitution. This residue is part of an NXS/T potential
N-linked glycosylation site (PNGS) that is highly conserved in the
donor inoculum and in the majority of globally sampled HCV
strains. Minor circulating E1E2 variants containing the amino
acid motifs SDHV and TDYD were detected in both the donor
inoculum and all recipientmice. Variants containing the TDYV/A
motif, which was undetectable in the donor population, were the
dominant variant posttransmission, irrespective of the recipient
chimeric-mouse viral population analyzed. An additional minor-
ity variant (SDYV) was detected at the first sampling time point
from the chimeric mice 666 and 931. This rare transitory variant
was undetectable in the donor population and at the second sam-
pling time point in chimeric mice 666 and 931. Together, these
data demonstrate that, while HVR1 sequences remain stable dur-
ing HCV transmission, key amino acid substitutions elsewhere in
E1E2 are selected for during transmission or during the initial
phase of infection in the new host.
Identificationof viral lineages that establish initial infection.
Individual donor/recipient transmission events (KP/594, KP/666,
KP/914, and KP/714) were further interrogated via BEAST analy-
ses to estimate the rates of evolution and the number of transmit-
ted viral lineages (defined as variants present in the inoculum that
became detectable, established lineages within the new host) (Fig.
5A to D). The estimated mean substitution rates ranged from 5
105 to 1 104 nucleotide substitutions per day. These analyses
also showed that HCV infection was established by multiple lin-
eages derived from the inoculum virus population, and in each
mouse, one or more lineages representing viruses containing the
TDYV/Amotif became dominant. Also, in eachmouse, therewere
one or more lineages associated with minor variants containing
the sequence motif TDYD or SDHV. These motifs were also pres-
ent in the predicted sequence of themost recent common ancestor
for each of these lineages. The estimated occurrence time of these
predicted ancestral sequences predated the time of the inocula-
tion, indicating that these variants were present at low frequency
in the original inoculum, rather than arising independently in
eachmouse postinoculation. In summary, these data demonstrate
that multiple variants established infection in each chimeric
mouse and point to a selective sweep occurring following trans-
mission, which resulted in selective outgrowth of lineages possess-
ing the motif TDYV/A.
HLA typing and epitope prediction. To investigate the possi-
bility that the observed substitutions at these key residuesmight be
due to reversion of escape mutations selected for by T-cell re-
sponses in the KP donor, patient HLA typing and mapping of
epitopes known or predicted to be presented by the donor HLA
class I alleles against the mouse consensus sequence were con-
ducted. Details of the donor HLA type and a map of the locations
ofHCVE1E2 epitopes towhichCD8T-cell responses restricted by
HLA-A*02, A*11, B*51, and Cw7 have been reported in the liter-
ature. None of the previously reported epitopes presented by these
HLA alleles overlapped with residue 198, 448, 474, or 570 are
presented in Fig. 6. Furthermore, when we used the SYFPEITHI
(http://www.syfpeithi.de/home.htm) and BIMAS (http://www
-bimas.cit.nih.gov/molbio/hla_bind/) websites to predict pep-
tides containing or adjacent to residues 198, 448, 474, and 570 that
were likely to be presented by the donor HLA class I alleles A*02,
A*11, B*40, B*51, and Cw7, both analyses failed to identify any
peptides at these sites with predicted binding to donor class I al-
leles comparable to that of the known T-cell epitope sequences we
tested in parallel. Therefore, we have no evidence that the amino
acid substitutions that were selected for in the immunocompro-
mised mice represented T-cell escape reversions posttransmis-
sion.
TheN448Dsubstitution confers enhanced viral entry.Tode-
termine whether the selective sweep observed in the mice was due
to increased entry fitness, we determined the relative entry effi-
ciency conferred by selected E1E2 variants present in the inocu-
lum and in the mice. Lentiviral pseudotypes carrying the various
E1E2s were generated and tested for the ability to infect both
Huh7.5 cells and primary hepatocytes. In Huh7.5 cells, the overall
level of infectivity conferred by the KP- andmouse-derived E1E2s
was consistently lower than (5%) the control H77c E1E2 (Fig.
7A). Therefore, we repeated the HCVpp assays using primary
hepatocytes (PHs) as the target cells, which improved the relative
infectivity of the KP- and mouse-derived E1E2 psuedoparticles
(Fig. 7B). In both PHs andHuh7.5 cells, the TDYVvariant (mouse
major variant) was significantly more infectious (P 0.001) than
the SNHVvariant (KP donormajority sequence). Theminor vari-
ants recovered from both the mice and the KP inoculum con-
ferred intermediate levels of infectivity. All N448D PNGS knock-
outs containing E1E2s had significantly increased capacity for
cellular entry compared to the N448-containing major variant
present in the inoculum. At the antibody concentration used, no
variants were demonstrably more sensitive to neutralization by
the anti-CD81 MAb 2s131. The significant increase in infectivity
demonstrated between the majority circulating pre- and post-
transmission E1E2s provides a likely mechanism for the selective
sweep that occurred following HCV transmission.
Mathematical modeling. To confirm whether the increased
FIG 2 Stability of HVR1 sequences upon transmission. (A) Alignment of HVR1 amino acid sequence variants (A to G) present in donor/recipient populations.
(B) Frequencies of HVR1 variants circulating within donor/recipient hosts.
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capacity for entry in vitro could result in the observed selective
outgrowth of the major mouse variant (TDYV/A) in vivo, the dy-
namics of competing HCV variants were mathematically mod-
eled. The majority of parameters required for the mathematical
analysis were determined from our own experimental data or
from previously published literature. However, some of those de-
rived from the literature are applicable only to mice with a func-
tioning immune system. To account for the difference between
these and our model, we scaled the relevant parameters to facili-
tate easy comparison between mouse models with functioning
and nonfunctioning immune systems. In this analysis, we treated
the population as two distinct variants: viruses containing key
residues combinations other than TDYV/A (variant 1, with de-
creased entry fitness) and viruses that possessed TDYV/A (variant
2, with increased entry fitness). Our model indicates that for a 
value of1, variant 2 will always outgrow variant 1, but the time
at which this occurs depends upon the parameters employed (Fig.
8). Decreasing the initial concentration of target cells delays the
time to outgrowth (the virions having fewer cells in which to rep-
licate), although increasing it makes little difference, suggesting a
FIG 3 Phylogenetic trees and patterns of substitution in sequences derived during experimental HCV transmission from the KP inoculum to chimericmice 594,
666, 714, and 931. Chimeric mouse 594 (A), 666 (B), 714 (C), and 931 (D)-derived sequences were analyzed via phylogenetic reconstructions (left panels) and
Highlighter plots (right panels) with pretransmission KP donor sequences included. TheML trees are rooted on the KP consensus (KP_con) sequence, which is
the master sequence in corresponding Highlighter plots. The Highlighter plots depict the relative locations of synonymous (green vertical bars) and nonsyn-
onymous (red vertical bars) substitutions in each E1E2 amplicon compared to the pretransmission master sequence. A schematic representation of the E1E2
gene, depicting the locations of PNG sites and the E1/E2 boundary, is provided above the Highlighter plots for the purposes of positional referencing. The scale
bar is proportional to the genetic distance and represents 0.0005 nucleotide substitution per site.
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saturation effect. Similarly, lowering the rate of target cell death
also slows down the process.
When each variant is given equal entry fitness, variant 1 (due to
its higher initial concentration) will remain dominant throughout
the time course, while increasing the relative fitness of variant 2
provides sufficient advantage to ensure that it becomes the dom-
inant population. For example, if the rate of infection of variant 2
is four times that of variant 1 (i.e., 1.2 106ml virion1 day1), it
will comprise 60% of the total viral load after only 20 days, despite
starting at a drastically lower initial concentration. Larger in-
creases in this rate can result in variant 2 becoming dominant
almost immediately. Given the quantitative sensitivity of the
model to the parameter choice, it would be unwise to make de-
tailed predictions about the time taken to achieve dominance, but
it is clear that a relatively subtle difference in the ability of a variant
to infect a target cell can result in its overtaking all other variants in
a matter of days.
DISCUSSION
In this study, the SCID/Alb-uPA chimeric mouse model was uti-
lized to study HCV population dynamics following transmission.
Such studies in natural infection have been hampered due to the
difficulty in obtaining donor-recipient blood samples. Our data
also highlight the fact that studying full-length E1E2, rather than
gene fragments such as HVR1, yields important insight into de-
terminants that shape HCV entry and transmission. Indeed, this
study demonstrates that key E1E2 amino acid substitutions that
predominate in viral populations following transmission are lo-
cated outside HVR1.
Importantly, we used SGA to recover viral envelope genes from
donor and recipient mice, followed by direct sequencing. This is
preferable to standard bulk amplification and cloning, as it ex-
cludes polymerase-induced nucleotide misincorporation, ampli-
con resampling, selective amplification of specific isolates, cloning
bias, and the generation of in vitro recombinants via polymerase
template switching (56). Furthermore, SGA is not affected by the
limitations of ultradeep-sequencing (UDS) technologies, where
assigning linkage of the various substitutions remains challenging.
The SGA approach has become the gold standard for sequence-
based studies for a range of infectious agents (2, 4, 28, 33, 35, 56,
57) yet is still widely ignored within the HCV field.
Analysis of the E1E2 sequences derived from the inoculum and
recipient mice revealed that the sequences formed two main
clades, one containing sequences derived wholly from the inocu-
lum and another containing mainly mouse-derived sequences.
Surprisingly, there was no evidence of sequence clustering accord-
ing to the recipient mouse. This contrasts with studies of com-
mon-source transmissions of HCV, where there is clear evidence
of recipient/patient-specific clades (38). Factors that might shape
patient-specific lineages include differential donor selection pres-
sures (e.g., host-specific humoral and cellular immunity) or sim-
ply a founder effect arising from inoculation with low titers of
genetically distinct variants. The genetic signature of the founder
effect (establishment of infection from a single strain) is indistin-
guishable from a selective sweep (a selectively advantageous ge-
netic variant is swept to fixation in the recipient) in contempora-
neously sampled populations. However, knowledge of the titer
and genetic composition of the inoculumallows us to assess which
of these two competing evolutionary scenarios is most likely to
have given rise to the change in variant frequencies observed in the
recipient chimeric mice. We believe our data indicate that a selec-
tive sweep occurred, whereby variants that were present at unde-
tectable frequencies in the donor inoculum became the major
variant circulating in all experimentally infected chimeric mice.
Coalescent analysis of individual transmission events indicated
that one ormore variants harboring the advantageous E1E2motif
were likely present in the inoculum rather than arising indepen-
dently in each chimeric mouse, posttransmission.
While the KP inoculum used to infect each chimeric mouse
possessed limited E1E2 genetic diversity, around 86% of recov-
ered E1E2s from the donor serumwere unique variants. Although
2.3 105 virions were used to seed each new infection, Bayesian
coalescent analyses indicate that only a restricted number of vari-
ants established each initial infection. All E1E2s recovered post-
transmission contained the N448D PNGS knockout, with selec-
tive amplification of variants bearing the TDYV/A motif
occurring in all recipient chimeric mice. Indeed, increasing fre-
quency of TDYV/A-bearing variants between the two sampling
points was observed in all four animals (Fig. 4B), suggesting this
variant ismoving toward fixation in each population and pointing
to a selective sweep occurring upon experimental HCV transmis-
sion. However, we were unable to detect any variants transmitted
possessing the SNHV motif, which was the majority circulating
strain in the inoculum. Therefore, we are unable to discount the
possibility that the marked shifts observed in population compo-
FIG 4 Identification of key residues involved in HCV transmission and the
frequencies of key residue combinations in donor and recipient viral E1E2
populations. (A) Schematic E1E2 diagram depicting the locations of four key
residues involved in transmission. The positions of conserved potential N-gly-
cosylation sites are indicated above the E1E2 protein. The coordinates given
are relative to the homologous positions in the H77 reference strain polypro-
tein (accession no. NC_004102). The colored vertical columns located below
key residues indicate consensus amino acids present in the E1E2 SGA popula-
tions of donor and four recipient chimeric (top), as well as consensus, amino
acid sequences derived from bulk amplified RNA obtained from eight other
transmission experiments using the same KP inoculum (bottom). (B) Fre-
quencies of key residue combinations circulating within donor/recipient
hosts. TP1, time point 1; TP2, time point 2.
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sition posttransmission may be due to strong purifying selection
against SNHV-bearing variants. In this scenario, the predominant
variant in the inoculum possesses a deleterious phenotype in the
chimeric mice and is removed from circulating populations via
purifying selection.
In our transmission experiments, the major HVR1 amino acid
variants pre- and posttransmission were identical, which is in
agreement with other transmission studies (34, 37, 54, 60). HVR1
is often used as a surrogate marker for entire E1E2 genetic varia-
tion, and the HVR1 clonotype has been used as a basis for choos-
ing E1E2 clones for downstream analyses (20). However, our data
indicate that this approach can be flawed. In all of the separate
transmission experiments, the major HVR1 variants were identi-
cal, and differences in entry fitness were associated with 4 amino
acid residues (198, 448, 474, and 570) outside HVR1. All post-
transmission E1E2s harbored an N¡D PNGS knockout, which
presumably conferred a selective advantage in each chimeric
mouse host. A PNGS knockout at position 448 (corresponding to
glycan E2N4) has previously been shown to abrogate H77 E1E2
pseudoparticle infectivity (21), although a similar knockout does
not abrogate HCVcc infectivity (24). In the HCVcc system, the
removal of a glycan at position 448 has been shown to render
JFH-1 E1E2 more susceptible to antibody-mediated neutraliza-
tion (24). Therefore, the absence of neutralizing antibodies and
the increased fitness of the TDYV variant provide a likely mecha-
nism for the selective amplification of this strain in all recipient
chimericmice. Unfortunately, wewere unable to obtain any of the
original KP serum to perform neutralization tests to validate this
hypothesis.
In our hands, the KP- and mouse-derived E1E2 clones con-
ferred very low-level infectivity in HCVpp when used to infect
Huh7.5 cells. However, infectivity relative toH77 E1E2wasmark-
edly increased when primary hepatocytes were used as the target
cell. This contrasts with a previous study of HCVpp entry using
FIG 5 Identification of the number of transmitted lineages for each experimental infection event. Shown are donor/recipient pairs KP/594 (A), KP/666 (B),
KP/714 (C), andKP/931 (D). The lineages are color coded according to key residue combinations: red, SNHV; green, SDHV; yellow, TDYD; orange, SDHV; blue,
TDYV/A. The scale bar located below each tree is proportional to the time. The units correspond to days, with 0 representing the final sampling date for each
individual chimeric mouse and the dotted line representing the time of experimental infection. Lineages/variants present in the KP inoculum are indicated by
asterisks.
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E1E2 derived from a liver transplant setting, where primary hepa-
tocytes were less efficient at supporting entry than Huh7.5 cells
(20). It is unclear what underlies this discrepancy although hepa-
tocyte donor-specific genetic differences may play a role. Impor-
tantly the infectivity conferred by the majority mouse-derived
E1E2 was significantly greater than that conferred by the major
variant present in the KP inoculum in both cell types. In the liver
transplant setting, variants with increased capacity for cellular en-
try and also increased resistance to autologous neutralizationwere
shown to preferentially reinfect the grafted liver (20). This report
also showed that one of these variants also demonstrated in-
creased fitness in a chimeric mouse. Given their neutralization-
resistant phenotype, it is intriguing that these variants did not
dominate pretransplantation. It is important to note that there are
significant differences between acute HCV infection and liver
graft reinfection following transplantation, not least the presence
of host immunity, which will help shape the evolution of the re-
infecting virus. Also, corticosteroids given post-liver transplanta-
tion have been shown to increase the infectivity of HCV by alter-
ing the expression levels of entry factors (10, 11), which may also
help to select for particular viral variants in this unique setting.
Selective outgrowth of specific viral variants could also be
driven by host factors, including genetic polymorphisms. Tomin-
imize this effect, we used mice that had hepatocyte grafts from a
number of distinct donors. HCV infection of recipient chimeric
mice is dependent on a high percentage of human grafts in each
SCID/Alb-uPA mouse (42). It has previously been demonstrated
that HCV does not replicate in mouse hepatocytes (15, 39). Thus,
the productive viral replication and infectious-particle produc-
tion observed in recipient chimeric mice can only be sustained by
engrafted human hepatocytes. The observed E1E2 adaptations in
recipient chimeric-mouse virions will therefore have been driven
to fixation by their ability to enter and replicate in human hepa-
tocytes, indicating that the chimeric-mouse system is a useful sur-
rogate model to enable interrogation of HCV transmission to an
FIG 6 Locations of reported T-cell epitopes restricted by the donor KP’s HLA
class I alleles in the E1E2 sequence. The mouse consensus E1E2 amino acid
sequence is shown, with the four amino acid substitutions associated with
establishment of productive infection following HCV transmission high-
lighted in pink. Sequences corresponding to the locations of reported T-cell
epitopes restricted by the donor KP’s HLA class I alleles are highlighted in
different colors, with the peptide sequence(s) to which T-cell responses were
demonstrated shown above them.
FIG 7 Infectivities of HCVpp bearing donor and recipient variant E1E2s in
hepatoma cells and primary hepatocytes. (A and B) HCVpp infectivities con-
ferred by themajor inoculum E1E2 variant (SNHV), themajor recipient E1E2
variant (TDYV), and two minor variants present in both the inoculum and
recipient mice (SDHV and TDYD). Mean infectivity values are expressed as
percentages of the infectivity conferred by H77c E1E2 in Huh7.5 cells (A) and
PHs (B). Infectivity assays were performed in the presence or absence of anti-
CD81monoclonal antibody (MAb) 2s131, and the values presented aremeans
for six replicates from two independent experiments with associated error bars
(standard deviations). The associated significance values indicate that the
TDYV variant confersmore efficient entry than the SDHV, TDYD, and SNHV
variants. Additionally, both the SDHV and TDYD variants confer improved
capacity for entry compared to the SNHV variant. Differences in the mean
infectivities conferred by each HCV E1E2 were assessed using analysis of vari-
ance (ANOVA) with infectivity: ***, P  0.001. (C) p24 concentrations for
each of the variant HCVpp preparations used to infect Huh7.5 cells or PHs.
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HCV-naïve host and establishment of initial infection prior to
seroconversion.
In summary, we have applied a robust methodological ap-
proach to enable interrogation of the dynamics of HCV transmis-
sion in the SCID/Alb-uPA chimeric-mousemodel. Our data show
that the environment of the new host dramatically alters the virus
population following transmission. Identification of the molecu-
lar determinants of transmitted E1E2 glycoproteins that establish
initial infection will be relevant to the design of vaccines and other
preventative strategies.
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